TEST:

SureSeq™ CLL + CNV Panel

"Today, OGT (Oxford Gene Technology) announced the launch of its newly updated NGS SureSeqTM CLL + CNV V3 Panel, which further incorporates their highly sensitive proprietary bait designs to offer more expansive coverage of disease-associated genes and enhanced CNV detection. This new panel now offers users more comprehensive variant detection to improve confidence in classification of CLL research samples to strengthen the understanding of CLL progression. ."

Our analysis revealed that specific genetic mutations and chromosomal alterations are strongly associated with the disease's course and patient prognosis. Particularly, the presence of unmutated IGHV and TP53 mutations emerged as key indicators of a more aggressive disease course and shorter treatment-free intervals. These findings underscore the critical role of advanced genetic testing in identifying patients who may require more intensive treatment and monitoring.

"OGT...announces the opening of state-of-the-art facilities within the Oxford Technology Park. The move represents a multi-million-pound investment, fuelled by consistent company growth and growing customer demand. Equipped with cutting-edge technology, the facilities will drive development of OGT’s trusted SureSeq™ next generation sequencing (NGS) product portfolio, as well as deliver expert-led training and enhanced opportunities for collaboration."

"OGT, A Sysmex Group Company...and Intelliseq...are delighted to announce the release of GeneSpect™ Somatic Reporter for use with OGT’s SureSeq™ portfolio of next generation sequencing (NGS) panels. This advanced analytical reporting solution pairs state-of-the-art variant interpretation and reporting with OGT’s class-leading NGS panels and bioinformatics solutions. Users of SureSeq Myeloid panels can now benefit from insightful tertiary reporting for all myeloid malignancy content and variants with the GeneSpect Somatic Reporter."